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Abstract
Despite the fact that inflammatory bowel disease (IBD) has still no recognised therapy, treatments which have proven at least mildly successful
in improving IBD symptoms include anti-inflammatory drugs and monoclonal antibodies targeting pro-inflammatory cytokines. Resveratrol,
a natural (poly)phenol found in grapes, red wine, grape juice and several species of berries, has been shown to prevent and ameliorate
intestinal inflammation. Here, we discuss the role of resveratrol in the improvement of inflammatory disorders involving the intestinal mucosa.
The present review covers three specific aspects of resveratrol in the framework of inflammation: (i) its content in food; (ii) its intestinal
absorption and metabolism; and (iii) its anti-inflammatory effects in the intestinal mucosa in vitro and in the very few in vivo studies present
to date. Actually, if several studies have shown that resveratrol may down-regulate mediators of intestinal immunity in rodent models, only two
groups have performed intervention studies in human subjects using resveratrol as an agent to improve IBD conditions. The effects of
resveratrol should be further investigated by conducting well-designed clinical trials, also taking into account different formulations for the
delivery of the bioactive compound.
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Introduction
Inflammatory bowel disease (IBD) is the generic term used to
describe a group of chronic diseases characterised by uncon-
trolled inflammation of the intestinal mucosa(1). The aetiology of
IBD is currently unknown. However, IBD progression is influ-
enced by genetic factors, dysregulation of immune responses,
dysfunction of the mucosal barrier, and loss of immune tolerance
to enteric flora(2). Altogether, these factors result in the production
of inflammatory mediators such as oxygen and nitrogen reactive
species, prostaglandins and cytokines, which can contribute to an
uncontrolled inflammatory response that ultimately culminates in
irreversible tissue damage. The two main forms of IBD are Crohn’s
disease and ulcerative colitis (UC), each differing in location and
severity. Crohn’s disease is known to affect multiple sections of
the gastrointestinal tract, whereas UC is limited to the rectum and
colon(3,4). Furthermore, IBD patients with an extended history of
the disease maintain a high risk of developing colon cancer(5). A
greater understanding of the pro-inflammatory cytokine networks
underlying enteric mucosa inflammation has led to the develop-
ment of targeted anti-TNF-α therapies. Additionally, recent
studies have been aimed at exploring novel treatments for IBD,
including regulatory T cell therapy, the use of anti-inflammatory
cytokines – for example, IL-10 – and stem cell-based therapies(6,7).
Previous epidemiological studies have identified a correlation
between the consumption of red wine and a decreased incidence
of heart disease, known as the ‘French paradox’(8). This correla-
tion might be due to the presence of resveratrol, a known anti-
oxidant, anti-inflammatory, and anti-proliferative compound,
in red wine(9). In vitro and in vivo studies have also shown
that resveratrol ameliorates IBD by decreasing mucosal
inflammation(10).
In the present review, we will discuss the effects of resvera-
trol on IBD pathology, and – by reviewing data from in vitro,
animal and human studies – we will describe the mechanisms
utilised by resveratrol that mediate its anti-inflammatory activity.
We will begin by characterising the natural occurrence and
biosynthesis of resveratrol, followed by describing its metabo-
lism. Finally, we will focus on how resveratrol improves the
prognosis in patients with IBD.
Resveratrol occurrence and synthesis
Resveratrol (3,4′,5-trihydroxystilbene) is a naturally occurring
stilbene found in a variety of plant species (for example, grapes,
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groundnuts, Japanese knotweed, and several species of berries,
such as blueberries, bilberries and cranberries), and exists as
both cis- and trans-isomers, the latter being the most commonly
found and stable form(11). The compound was first isolated in
1940 from white hellebore (Veratrum grandiflorum O. Loes)(12)
and, in 1963, was found in Japanese knotweed (Polygonum
cuspidatum), currently one of the principal sources of resver-
atrol found in nature(13). In 1976, Langcake & Pryce(14) detec-
ted, for the first time, trans-resveratrol in grapevines (Vitis
vinifera), where resveratrol is synthesised in response to exo-
genous stimuli such as fungal damage (for example, Botrytis
cinerea) or UV light. Resveratrol was later found to be highly
photosensitive and susceptible to UV-induced isomerisation, as
more than 80% of trans-resveratrol in solution is converted to
cis-resveratrol if exposed to light for 1 h(15). The final step of
resveratrol biosynthesis involves stilbene synthase-mediated
condensation of three molecules of malonyl-CoA with one
molecule of p-coumaroyl acid, generating trans-resveratrol and
four molecules of CO2
(16) (Fig. 1). In the 1990s, resveratrol was
identified as a component of red wine(17) and, since then, it has
been studied extensively. In 2013, Tomé-Carneiro et al.(18)
estimated more than 22500 publications on resveratrol in three
databases of literature (PubMed, Scopus, ISI Web of Knowl-
edge). Resveratrol is produced especially in the skins of
grapes(19), and it is extracted in the maceration process during
the production of red wine(20). The amount of resveratrol
present in red wine is influenced by grape variety, soil, climate
and winemaking techniques, including manipulation of the
amount of time that grape skins remain during the fermentation
process(17,21). Resveratrol occurs in wine both in its unconju-
gated, aglycone, form and as resveratrol glucoside (resveratrol-
3-O-β-D-glucoside, often referred to as piceid), both in
cis and trans arrangements(22,23). The concentration of piceid
is approximately three times higher than that of aglycone
resveratrol in wines originating from Spain and Portugal(24,25).
Absorption, bioavailability and metabolism of resveratrol
It has been previously demonstrated that phenolic compounds,
present in the plasma at low (nanomolar to micromolar) con-
centrations, are found in the intestine at much higher levels
immediately after the consumption of foods and supplements
rich in these compounds(26). Thus, phenolic compounds may
play a pivotal role in the modulation of the colon micro-
environment in both healthy and pathological conditions(27,28).
Likewise, resveratrol has a rapid rate of uptake and is absorbed
in large quantities by enterocytes. However, plasma con-
centrations of resveratrol are generally low due to high rates of
intestinal and hepatic metabolism(29). In one study, the max-
imum plasma concentration (Cmax) of resveratrol, evaluated in
human subjects following administration of a high concentra-
tion of resveratrol, was found to be within the range of 0·3 to
2·4 µmol/l after approximately 1·5 h. Here, the authors descri-
bed two main types of resveratrol metabolites, resveratrol-3-
sulfate and resveratrol monoglucuronides, that were found in
the plasma at concentrations of up to about 20-fold higher than
that of resveratrol itself(30).
Previous studies have also characterised the rate of uptake of
resveratrol in vitro and in vivo. Resveratrol, upon entering the
small intestine, crosses the enterocyte apical membrane by
either passive diffusion or carrier-mediated transport. The
aglycone form of resveratrol is absorbed by passive diffusion
into human epithelial colorectal adenocarcinoma cells (Caco-2)
across the apical membrane, whereas the piceid form is actively
transported via Na-dependent transporter proteins(31) (Fig. 2).
The transepithelial transport of piceid occurs at a higher
rate compared with the aglycone form of resveratrol(32).
Nevertheless, piceid is then hydrolysed by β-glycosidases
that are produced by the intestinal microflora, promoting the
absorption of the aglycone form(33). Phase II metabolism of
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Fig. 1. Synthesis of resveratrol. PAL, phenylalanine ammonia-lyase; C4H,
cinnamate 4-hydroxylase; 4CL, 4-coumarate-CoA ligase; STS, stilbene
synthase.
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resveratrol occurs in the gut, where resveratrol is conjugated
with sulfate by sulfotransferase or with glucuronic acid by
uridine-5′-diphosphate-glucuronosyltransferase, yielding meta-
bolites resveratrol sulfates and resveratrol glucuronides,
respectively(34,35). Three derived metabolites have been
identified: resveratrol-3-glucuronide, resveratrol-4′-O-glucur-
onide and resveratrol-3-O-sulfate. In addition, intestinal bacteria
are able to convert resveratrol to dihydroresveratrol, which is
also transported into enterocytes and metabolised to sulfated
or glucuronidated forms(35,36).
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Fig. 2. Absorption and metabolism of resveratrol. After ingestion, resveratrol may be absorbed as glycoside (G-RSV) and then cleaved to the aglycone form of
resveratrol (RSV) by cytosolic glucosidase (CBG). Alternatively, this process can occur in the lumen with the action of β-glycosidases (BG) produced by the intestinal
microflora (MF). Within enterocytes, RSV is rapidly metabolised to resveratrol glucuronides (RSV-glucuronides) and resveratrol sulfates (RSV-sulfates) via uridine-5′-
diphosphate-glucuronosyltransferase (UGT) and sulfotransferase (SULT), respectively. There is some efflux of these metabolites back into the small intestine, which
involves multidrug resistance protein (MRP) 2 and breast cancer resistance protein (BCRP) 1. Resveratrol conjugates can also efflux though the basal side of the
enterocytes via MRP3. RSV can passively diffuse through the enterocyte basal membrane. Once in the bloodstream, resveratrol and its metabolites reach the liver,
where they are further glucuronidated or sulfated. Resveratrol and its conjugates can be recycled back to the small intestine through the bile or excreted via urine.
SGLT1, sodium-dependent glucose cotransporter-1; A, albumin.
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In an ex vivo study using an isolated rat small intestine perfusion
model, Andlauer et al.(37) showed that 46% of the luminally
administered resveratrol was absorbed by the small intestine, 21%
of which appeared in vascular tissue while another 2% was located
inside the intestine. In the luminal effluent, 40% of resveratrol was
unconjugated, 11% was glucuronidated, and 3% was sulfated.
Here, a likely explanation for the presence of resveratrol conjugated
metabolites in the intestinal lumen is the presence of apically
located efflux transporters(38), such as multidrug resistance protein
(MRP) 2, MRP3 and breast cancer resistance protein (BCRP) 1,
which are all present in the membrane of the enterocytes(39). MRP3
is present in the basolateral membrane of enterocytes, whereas
BCRP1 is present in the apical membrane(40). When BCRP1 is
inhibited, the efflux of resveratrol glucuronide and sulfate con-
jugates is diminished without affecting the absorption of resveratrol.
BCRP1 is the most important efflux transporter for sulfate con-
jugates, as evidenced in BCRP1 knockout mice, where sulfate and
glucuronide metabolite efflux was inhibited by 95 and 70%,
respectively(41). Glucuronidated resveratrol is also a substrate of
MRP2(31). Kaldas et al.(34) showed that treatment with low con-
centrations of resveratrol resulted in the production of resveratrol
metabolites primarily on the apical side of Caco-2 cells. On the
other hand, using high concentrations of resveratrol, sulfate con-
jugates were exported towards the basolateral side, where the
MRP3 transporter is localised, due to the saturation of transporters
on the apical side. Therefore, the trans-resveratrol conjugates that
are not transported to the apical side by MRP2 and BCRP1 are
transported by MRP3 into the bloodstream(42). There, the metabo-
lites are hydrolysed and converted back into an aglycone form by
the intestinal microflora, and the excreted compounds can be
reabsorbed back into the interior of the enterocytes(38).
Once resveratrol has been metabolised by intestinal epithelial
cells, it is transported to the liver and enters hepatocytes by pas-
sive and carrier-mediated transport(41). After crossing the hepato-
cyte membrane, resveratrol is rapidly conjugated and metabolised
into its glucuronidated and sulfated derivatives(43). All forms of
resveratrol are then subsequently excreted in the bile(44).
In the blood, transport of resveratrol is accomplished through
its association with lipoproteins, Hb, albumin and serum pro-
teins as it is carried to and from various organs and tissues,
followed by elimination in the urine(45).
Because resveratrol is extensively metabolised in the gastro-
intestinal tract and the liver, it will be crucial for future studies
to determine if the biological beneficial effects mediated by
resveratrol are due not only to the parent compound but also
to their metabolites, as has been suggested by Aragonès
et al.(46) (for a full review, see Del Rio et al.(47)).
Effects of resveratrol on inflammation and inflammatory
bowel disease
Inflammatory bowel disease pathophysiology
The intestinal wall is protected by epithelial cells attached via
tight junctions that form a seal against the lumen of the intestinal
tract. These epithelia provide a physical barrier between the
internal environment and luminal microbes, representing the
first line of defence of mucosal immunity(48). Impairment of this
barrier, due to the dysregulation of tight junctions, leads to
increases in permeability and infection(49). Loss of intestinal
barrier integrity also promotes abnormal immune and inflam-
matory responses that are triggered by increased interactions
between gut microbiota and the host’s immune system, a key
factor that precedes UC and Crohn’s disease (Fig. 3)(4,50,51).
Luminal microbes that cross the epithelial barrier and multi-
ply within host tissues are recognised by macrophages that
reside in the lamina propria of the mucosa. Macrophages act as
antigen presenters for T lymphocytes and are responsible for
secreting cytokines and chemokines that attract and activate
other immune cells, such as lymphocytes and neutrophils(52).
Thus, circulating leucocytes are ‘arrested’ at the site of inflam-
mation due to the production of selectins and factor VIII by
endothelial cells. In these instances, selectins allow for the
adhesion of lymphocytes and granulocytes to the target tissue,
and factor VIII promotes the activation of the complement
pathway and the kinin cascade, thereby increasing intestinal
permeability(53). Macrophages and neutrophils represent the
primary source of reactive oxygen and nitrogen species present
within inflamed colon mucosa(54). These cells have a reduced
NADPH oxidase system that leads to the production of an array
of reactive oxygen and nitrogen species(55). Once activated,
NADPH oxidase transfers one electron from NADPH to mole-
cular oxygen, yielding one superoxide anion radical (O2
∙ − ).
Superoxide radicals are then converted into hydrogen peroxide
(H2O2) and the hydroxyl radical (HO
∙)(56). IBD patients with
intestinal inflammation show elevated levels of reactive species.
Consequently, mucosal damage caused by high levels of oxi-
dative stress plays a key role in the pathogenesis of IBD(57).
The nuclear factor κ light-chain-enhancer of activated B cells
(NF-κB) is an important regulator of immunity that actively parti-
cipates in the progression of IBD. Once activated, NF-κB induces
the expression of genes involved in inflammation and immunity,
such as proinflammatory cytokines (TNF-α, IL-1β, IL-6, IL-12),
adhesion molecules, and enzymes such as inducible NO synthase
and cyclo-oxygenase-2 (COX-2)(58). The induction of cytokine
expression by NF-κB is responsible for the stimulation, activation
and differentiation of lamina propria immune cells, resulting
in persistent mucosal inflammation. For example, TNF-α acts as a
positive feedback signal that enhances the production of reactive
oxygen and nitrogen species, and NF-κB activation(59). The
uncontrolled production of reactive species in the mucosa
appears to play a significant role in IBD disease pathogenesis and
is responsible for the onset of IBD-related symptoms, including
diarrhoea, toxic megacolon and abdominal pain(60).
Another factor that has been shown to affect the pathology of
IBD is the IL-23/T helper 17 cells (Th17) pathway. This pathway
contributes to immune responses that regulate intestinal
inflammation in both animal models of colitis and human
patients with IBD(61). Importantly, experimental evidence has
confirmed the involvement of the IL-12/IL-23 pathway in the
pathogenesis of IBD(62,63).
Effects of resveratrol on inflammation in vitro
In vitro resveratrol’s effects on inflammation are summarised
in Table 1. Several groups have previously characterised the
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anti-inflammatory effects of resveratrol in intestinal cells. One
study focused on the protective effects of moderate to high
concentrations of resveratrol (10–50 µM) in Caco-2 cells exposed
to bacterial-derived lipopolysaccharides. Here, it was shown
that, in resveratrol-treated cells, lower levels of PGE2 correlated
with a decrease in COX-2 expression. Furthermore, resveratrol
inhibited NF-κB activation by reducing the rate of degradation
of IκB, an endogenous NF-κB inhibitor(64). A similar effect of
resveratrol on the activation of NF-κB was observed in Caco-2
cells and SW480 human colon adenocarcinoma cells treated
with lipopolysaccharides. High concentrations of resveratrol
(40 µM) abrogated the inflammatory responses of both cell types
by reducing the expression of Toll-like receptor 4 and inducible
NO synthase and decreasing the rate of IκB-α degradation(65).
Conversely, treatment with resveratrol (50 μM) did not inhibit
NF-κB activation in a different study that used Caco-2 cells but
instead exacerbated inflammatory responses(66).
5-Aminosalicylic acid (5-ASA) is a well-known pharmacological
compound used to treat IBD patients. One study assessed the
effects of pre-treatment with resveratrol and/or 5-ASA in HT-29
human colorectal adenocarcinoma cells after exposure to varying
combinations of pro-inflammatory cytokines. At a concentration of
25µM, resveratrol reduced PGE2 production, inducible NO syn-
thase and COX-2 expression, reactive species formation(67), and
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Fig. 3. Pathophysiology of inflammatory bowel disease. (1) The villi and intestinal glands, along with the lamina propria, associated gut-associated lymphoid tissue
andmuscularis mucosae, constitute the essential features of the small-intestinal mucosa. The glands are composed of a simple columnar epithelium that is continuous
with the epithelium of the villi. Intestinal epithelium cells include enterocytes, goblet cells, Paneth cells, enteroendocrine cells and M cells. Tight junctions in the
enterocytes establish a barrier between the intestinal lumen and the epithelial intercellular compartment. (2) Genetic and environmental factors induce the disruption of
tight junctions, causing increased permeability of the intestinal epithelium and increased uptake of commensal bacteria and microbial products. The recognition of
these by macrophages and dendritic cells leads to immune cell activation and cytokine (CK) production. (3) After activation by macrophages and dendritic cells, T-cells
produce various interleukins (IL) and TNF-α. (4) If acute mucosal inflammation cannot be resolved by anti-inflammatory mechanisms, chronic intestinal inflammation
develops. In turn, chronic inflammation may cause tissue destruction and complications such as fibrosis, stenosis and cancer. IFN-γ, interferon γ.
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activated the Nrf2 pathway, inducing the expression of antioxidant
and cytoprotective enzymes (haeme oxygenase 1 and glutamate
cysteine ligase)(68). Likewise, resveratrol efficiently decreased the
expression of phosphorylated signal transducer and activator of
transcription (STAT) 1, suggesting that the Janus kinase/signal
transducers and activators of transcription (JAK-STAT) pathway is
a key mediator of resveratrol’s anti-inflammatory activity(67).
Mitochondrial dysfunction plays an important role in IBD
pathogenesis, as oxidative stress and impaired ATP production are
key players in the development and progression of the disease.
Resveratrol, applied at extremely high concentrations (440µM),
protected Caco-2 cells against indomethacin-induced mitochondrial
dysfunction(69,70). Because resveratrol has an analogous structure to
rotenone (a complex I inhibitor), it has been proposed that one of
the mechanisms whereby resveratrol protects against mitochondrial
dysfunction is through binding to the ubiquinone site of complex I,
thus inhibiting the interaction between indomethacin and rote-
none(69). In agreement, resveratrol has been shown to inhibit the
mobilisation of Ca2+, the release of caspase-3, -9, and cytochrome c
from the mitochondria, and the induction of apoptosis in response
to cytotoxic concentrations of indomethacin(70). Therefore, resver-
atrol appears to potently inhibit mitochondrial dysfunction(71) and
prevent the onset of programmed cell death.
Resveratrol has also been tested in cultured cells derived
from patients with chronic obstructive pulmonary disease
(COPD), another disease characterised by the dysregulation of
immune responses. Culpitt et al.(72) showed that resveratrol,
at very high concentrations (about 600µM), inhibits inflammatory
cytokine release from alveolar macrophages isolated from
patients with COPD and alleviates inflammation.
With regards to the discrepancies in the concentrations of
resveratrol used in each study, it has been shown that admin-
istration of 0·5 g/d of resveratrol resulted in plasma concentra-
tions ranging from 2·4 µM (for a single dose)(30) to 4·24 µM (for
repeated doses)(73). Unfortunately, many in vitro studies have
used relatively high concentrations of the compound. There-
fore, it will be important for future research to focus on using
physiological conditions(46) in order to verify if resveratrol, at
concentrations normally found in serum, retains its anti-
inflammatory properties. However, resveratrol concentrations
within the environment of the gastrointestinal tract vary widely
among different patients and are frequently higher than those
found in the blood and peripheral tissues(74,75). Accordingly,
evaluation of resveratrol uptake and analysis of its metabolites
will be a crucial step in order to define the most effective
concentration of resveratrol for testing in vitro(76).
In conclusion, in vitro studies show that resveratrol, at
moderate to high concentrations, can modulate inflammatory
responses within intestinal cells by down-regulating NF-κB
activation and preventing mitochondrial dysfunction, providing
evidence for its potential use as a novel anti-inflammatory
compound in the framework of IBD.
Effects of resveratrol on inflammation in animal studies
In vivo studies using models for inflammatory intestinal
chronic diseases have contributed to our understanding of
the effects of resveratrol in IBD (Table 2). In a rat model of
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Table 2. Overview of the effects of resveratrol (RES) in experimental animal models of inflammatory bowel disease
Animal model RES dose, administration, duration Disease induction Effects Reference
Wistar rats 2 or 10mg/kg b.w. via oral
administration for 7 d
TNBS-induced colitis ↓ Ulcerative area, ↓ colon mass index, ↓ colon MPO activity, ↓ levels of
ICAM-1 and VCAM-1 in colon and serum, ↓ levels of GSH, MDA and
NO in colon
Abdallah & Ismael(78)
Wistar rats 1mg each animal or 1mg in 8mg
nanoparticles each animal via
rectal administration for 1 week
TNBS-induced colitis ↓ Colon histopathological injury score (only RES-loaded nanoparticles), ↓
colon weight/length (only RES-loaded nanoparticles), ↓ colon MPO
activity and GSH level (only RES-loaded nanoparticles), ↓ mRNA
expression levels of IL-1β, CINC-1, MCP-1 and ICAM-1 in colon, ↓
mRNA expression levels of IL-6, IL-12 and TNF-α in colon (only RES-
loaded nanoparticles), ↑ mRNA expression levels of MUC-2, MUC-3,
TFF-3 and villin in colon (only RES-loaded nanoparticles)
Lozano-Pérez et al.(10)
Wistar rats 5 or 10mg/kg b.w. per d via oral
administration for 1–24 h before
the induction of colitis and 24 h
later
TNBS-induced colitis ↓ Colon macroscopic damage (only at the higher concentration), ↓ colon
MPO activity (only at the higher concentration), ↓ IL-1β level in colon,
↔ PGE2 level in colon, ↓ PGD2 level in colon (only at the higher
concentration)
Martín et al.(77)
Wistar rats 10mg/kg b.w. per d via oral
administration for 1 d before the
induction of colitis and 14 d later
TNBS-induced colitis ↓ Colon macroscopic damage, ↓ colon MPO activity, ↓ TNF-α level in
colon, ↓ protein expression levels of COX-1, COX-2 and NF-κB p65 in
colon, ↑ PGE2 level in colon, ↔ PGD2 level in colon
Martín et al.(55)
Wistar rats 10mg/kg b.w. per d via
intraperitoneal injection for 5 d
TNBS-induced colitis ↓ Colon microscopy score, ↓ colon MDA level, ↔ activities of MPO, SOD
and CAT in colon, ↑ colon GPX activity
Yildiz et al.(79)
Wistar rats 25mg/kg b.w. via oral administration
for 30 d
Methotrexate-induced
colitis
↓ Levels of MDA, GSH and 8-OH-Gua in duodenum and jejunum, ↓ MPO
mRNA expression in duodenum and jejunum
Arslan et al.(94)
Wistar rats 10mg/kg b.w. via oral administration
for 14 d
Oxazolone-induced
colitis
↓ DAI, ↓ colon SphK1 activity, ↓ colon MPO activity, ↔ colon caspase-3
activity, ↓ colon histopathological injury score
Abdin(96)
Fischer F344 rats 1mg/kg per d (equivalent to
0·143mg/kg per d in human
subjects) via chow for 25 d
DSS-induced colitis ↓ Relative shortening of colon length, ↓ colon histopathological injury
score, ↓ COX-2, PTGES and PGE2 protein levels in colon, ↓ NO level in
colon, ↔ TBARS level in colon, ↔ FRAP
Larrosa et al.(80)
Lewis rats 40 or 100mg/kg b.w. per d via oral
administration for 28 d
PG-PS-induced
colitis
↓ mRNA expression levels of IL-1β, IL-6, TNF-α and TGF-β1 in caecum
(only at the higher concentration), ↔ mRNA expression levels of IGF-I,
procollagen type I and procollagen type III in caecum
Rahal et al.(93)
C57BL/6 mice 300 ppm (equivalent to 232mg/d in
human subjects) via chow for
1 week before the induction of
colitis and 5 weeks later
DSS-induced colitis ↓ Level of colon inflammation, ↓ iNOS, COX-2 and TNF-α protein levels in
colon, ↓ p53 and p53-phospho-Ser15 protein levels in colon
Cui et al.(98)
C57BL/6 mice 20mg/kg feed (approximately 3mg/
b.w.) via chow for 3 weeks
DSS-induced colitis ↓ Colon weight/length, ↓ levels of IL-1β and TNF-α in colon, ↑ colon level
of IL-10, ↓ protein expression levels of iNOS, COX-2 and PGES1 in
colon, ↓ p38 MAPK activation in colon
Sánchez-Fidalgo
et al.(82)
C57BL/6 mice 100mg/kg b.w. via oral
administration, every 2 d, for 10 d
DSS-induced colitis ↑ Colon length, ↓ TACE mRNA expression in colon, ↑ mRNA expression
levels of TIMP3 and SIRT1 in colon
Sharma et al.(86)
C57BL/6 mice 100mg/kg b.w. per d via oral
administration, every 2 d, for
14 weeks
DSS-induced colitis ↓ SAA level, ↓ colon histopathological injury score, ↓ IL-1β, IL-6, TNF-α,
and IFN-γ in serum, ↔ number of CD4+ T cells positive for IFN-γ in
spleen, ↓ number of CD4+ T cells positive for TNF-α in spleen, ↓
number of CD4+ T cells positive for IFN-γ and TNF-α in MLN and colon
LP lymphocytes, ↓ mRNA expression levels of COX-1 and COX-2 in
spleen, MLN, and colon LP lymphocytes, ↓ SIRT1 protein expression
level in colon LP lymphocytes, ↓ IκB activation in colon LP lymphocytes
Singh et al.(92)
C57BL/6 mice 100mg/kg b.w. per d via oral
administration for 11 d
DSS-induced colitis ↔ Colon length, ↔ spleen weight, ↔ colon MPO activity (MPO activity
in female mice < MPO activity in male mice), ↔ TNF-α protein level in
colon
Wagnerova et al.(84)
BALB/c mice 30 or 60mg/kg b.w. per d via oral
administration for 14 d
DSS-induced colitis ↓ Histological disease score in colon, ↓ colon MDA level, ↓ colon MPO
activity, ↓ activity of SOD and GPX in colon, ↓ mRNA and protein
expression levels of IL-8, TNF-α and IFN-γ in colon
Yao et al.(81)
BALB/c mice 50 or 1000mg/kg b.w. per d via oral
administration for 14 d
DSS-induced colitis ↓ Histological disease score in colon, ↑ relative number of Treg cells in
spleen (only at the higher concentration), ↓ relative number of Th17
cells in spleen
Yao et al.(90)
C57BL/6J mice 2·1mg/kg b.w per d (equivalent to
0·143mg/kg per d in human
subjects) via chow for 21 d
DSS-induced colitis ↔ Colon length, ↔ colon MPO activity, ↔ colon PGE2 level, ↓ levels of
sTNFR, MIP-1γ and CXCL9 in colon, ↔ levels of IL-6, IL-10 and GM-
CSF in colon, ↑ colon level of IL-3, ↔ serum levels of haptoglobin and
fibrinogen
Larrosa et al.(95)
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Table 2 Continued
Animal model RES dose, administration, duration Disease induction Effects Reference
ICR mice 10mg/kg b.w. per d via oral
administration for 7 d
DSS-induced colitis ↓ Shortening of colorectal length, ↓ iNOS protein level in colon, ↓ NF-κB and
IκB activation in colon, ↓ phosphorylation of ERK and STAT3 in colon
Youn et al.(83)
ApcMin/+ mice 100mg/kg b.w. via oral
administration for 5 weeks
DSS-induced colitis ↓ Polyp number and size in colon, ↔ polyp burden in small intestine, ↓
BrdU-positive cells in colon, ↓ PCNA-positive cells in colon, ↓
COX-2mRNA expression in small intestine, ↓ TNF-α protein level in
small intestine, ↓ IL-6mRNA and protein expression in small intestine, ↓
number of T cells, B cells, MDSC and NKT cells in MLN, ↑ expression
of miRNA-455 and miRNA-101b in intestinal mucosa
Altamemi et al.(97)
C57BL/10ScSn mice 20mg/kg b.w. via oral administration
for 10 d
Toxoplasma gondii-
induced ileitis
↑ Survival rate, ↓ body-weight loss, ↓ relative shortening of small-intestinal
length, ↓ ileal histopathological injury score, ↓ number of CD3+ T cells
in ileum, ↓ number of cells positive for MPO7 in ileum, ↑ number of cells
positive for FOXP3 and Ki-67 in ileum, ↓ IL-6mRNA expression in ileum
Bereswill et al.(91)
IL-10–/– mice 100mg/kg b.w. per d via oral
administration, every 2 d, for
28 weeks
Spontaneous chronic
colitis
↓ SAA level, ↓ IL-1β, IL-6, IL-12, TNF-α, IFN-γ and CCL5 levels in colon
and serum, ↓ colon histopathological injury score, ↑ number of MDSC
Singh et al.(88)
↑, Increase; ↔ , no change; ↓, decrease; 8-OH-Gua, 8-hydroxyguanine; b.w., body weight; BrdU, bromodeoxyuridine; CAT, catalase; CD3, cluster of differentiation 3; CD4, cluster of differentiation 4; CINC-1, cytokine-induced neutrophil
chemoattractant 1; COX-1, cyclo-oxygenase-1; COX-2, cyclo-oxygenase-2; CXCL9, chemokine (C-X-C motif) ligand 9; DAI, disease activity index; DSS, dextran sulfate sodium; ERK, extracellular signal-regulated kinase; FOXP3, forkhead box P3;
FRAP, ferric-reducing ability of plasma; GM-CSF, granulocyte-macrophage colony-stimulating factor; GPX, glutathione peroxidase; GSH, reduced glutathione; ICAM-1, intercellular adhesion molecule 1; ICR, Institute for Cancer Research; IFN-γ,
interferon-γ; IGF-I, insulin-like growth factor 1; iNOS, inducible NO synthase; IκB, inhibitor of NF-κB; Ki-67, protein encoded by MKI67, marker of proliferation Ki-67 gene; LP, lamina propria; MAPK, mitogen-activated protein kinase; MCP-1, monocyte
chemoattractant protein 1; MDA, malondialdehyde; MDSC, myeloid-derived suppressor cells; MIP-1γ, macrophage inflammatory protein-1 γ; miRNA, microRNA; MLN, mesenteric lymph nodes; MPO, myeloperoxidase; mRNA, messenger RNA;
MUC-2, mucin 2; MUC-3, mucin 3; NF-κB, nuclear factor κ light-chain-enhancer of activated B cells; NKT, natural killer T; p38, p38 protein; p53, p53 protein; p53-phospho-Ser15, p53 protein phosphorylated at Ser15; p65, p65 protein; PCNA,
proliferating cell nuclear antigen; PGES1, PGE synthase 1; PG-PS, peptidoglycan-polysaccharide; ppm, parts per million; PTGES, PGE synthase; SAA, serum amyloid A; SIRT1, sirtuin 1; SOD, superoxide dismutase; SphK1, sphingosine kinase 1;
STAT3, signal transducer and activator of transcription 3; sTNFR, soluble TNF receptors; TACE, TNF-α-converting enzyme; TBARS, thiobarbituric acid-reactive substances; TFF-3, trefoil factor 3; TGF-β1, transforming growth factor β1; Th17, T
helper 17 cells; TIMP3, metalloproteinase inhibitor 3; TNBS, 2,4,6-trinitrobenzenesulfonic acid; Treg, regulatory T cells; VCAM-1, vascular cell adhesion molecule 1.
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An overexpression of TNF-α-converting enzyme (TACE) has
been observed in the colon tissue of human subjects with
IBD(85), and evidence suggests that resveratrol can ameliorate
the intestinal inflammation, through inhibition of TACE, in
C57BL/6 mice with DSS-induced colitis(86).
The IL-10–/– mouse model lacks a functional version of the anti-
inflammatory cytokine IL-10(87), and has been widely used as a
model of IBD. Singh et al.(88) showed that the oral administration
of resveratrol ameliorates chronic colitis in IL-10–/– mice by the
induction of myeloid-derived suppressor cells (MDSC) and
lowering of both mucosal and systemic inflammatory cytokine
responses. MDSC possess strong immunosuppressive activities(89),
and their modulation has potential therapeutic effects on inflam-
matory diseases such as IBD.
Administration of moderate to high doses of resveratrol (50
and 100mg/kg) was able to regulate the imbalance between
Th17 and regulatory T (Treg) cells through reducing the num-
ber of Th17 cells and up-regulating the number of Treg cells in a
DSS murine model of UC(90).
A Toxoplasma gondii inflammation model has also been
used to study the protective effects of resveratrol. Bereswill
et al.(91) observed that administration of resveratrol results in:
(i) a high proliferation rate of intestinal epithelial cells in the ileal
mucosa, (ii) a reduction of CD3+ T lymphocytes, (iii) a decrease in
the levels of inflammatory cytokines such as interferon-γ and TNF-α
in the lamina propria, (iv) a reduction in neutrophil recruitment,
and (v) a reduction in reactive species production. Furthermore,
treatment with resveratrol induced changes in the gut microbiota
(fewer proinflammatory enterobacteria and enterococci, and
higher anti-inflammatory lactobacilli and bifidobacteria) and a
decrease in bacterial translocation(91). It also up-regulated sirtuin 1,
suppressed Th1 lymphocytes(92), and decreased the levels of
transforming growth factor β1, all of which led to a decrease in
caecal wall fibrosis(93).
Arslan et al.(94) found that resveratrol is able to protect against
gastrointestinal toxicity of chemotherapeutic agents such as
methotrexate, demonstrating that it can reduce the oxidative stress
and induce antioxidant responses in duodenal and jejunal tissues.
The application of resveratrol is limited because of its low
oral bioavailability. Thus, attempts to increase its bioavailability
include its encapsulation in silk fibroin nanoparticles. Admin-
istration of resveratrol nanoparticles in rats treated with TBNS
and forced to undergo IBD resulted in an increased anti-
inflammatory effect compared with treatment with resveratrol
alone, underlining a synergy between the particles and
resveratrol or an enhanced anti-inflammatory effect of resver-
atrol. Unsurprisingly, mice treated with encapsulated resveratrol
exhibited decreases in myeloperoxidase activity and expression
of TNF-α, IL-1, IL-6 and IL-12. Thus, the use of silk fibroin
nanoparticles may be an attractive strategy for the controlled
release of resveratrol to target intestinal inflammation(10). Yet
another approach to increasing resveratrol bioavailability
involved using a DSS murine model of inflammation. Here,
resveratrol prodrugs and pro-prodrugs were applied to
decrease resveratrol metabolism and to increase the availability
of resveratrol in the colon. These prodrugs and pro-prodrugs
restored mucosal barrier function in response to DSS and
enhanced the beneficial effects of resveratrol on colon
mucosa(95). Altogether, it appears that further investigation into
the potential effects of prodrugs and nanoparticles as methods
to improve resveratrol’s bioavailability is warranted.
Patients with IBD have an elevated risk of developing colon
cancer. Abdin(96) carried out a study to investigate the effects of
resveratrol on sphingosine kinase 1 (SphK1) activity and
apoptosis using a rat model of oxazolone-induced UC. SphK1
has been reported to mediate inflammatory, pro-survival and
pro-proliferative signalling pathways. This study demonstrated
that the activation of SphK1 plays a key role in the pathogenesis
of UC and confers an increased risk of colon tumorigenesis.
Furthermore, resveratrol was shown to reduce inflammation
and apoptosis, possibly due to the inhibition of SphK1(96).
Additionally, it has been shown by Ibrahim Altamemi et al.(97)
that resveratrol inhibited the formation of polyps, and reduced
cell damage and proliferation of epithelial cells in the intestinal
mucosa in mice exposed to DSS. In this study, resveratrol also
decreased the presence of inflammatory cells (T, B and natural
killer T lymphocytes) and decreased the levels of circulating
cytokines. Finally, microarray analysis identified two microRNA
(miRNA), miRNA-101b and miRNA-455, with anti-inflammatory
properties that were up-regulated in response to resveratrol(97).
Similarly, Cui et al.(98) observed that resveratrol improves the
intestinal inflammation and down-regulates the markers of
inflammation (inducible NO synthase, COX-2 and TNF-α) and
the sensors of inflammatory stress (p53 and p53-phospho-Ser15)
in mice treated with DSS. Tumour incidence and multiplicity
also decreased with resveratrol treatment.
In summary, resveratrol has been shown to have potent anti-
inflammatory effects in vivo. It decreases neutrophil infiltration
in the intestinal mucosa, inhibits TNF-α production and NF-κB
activation, and represses intestinal tumorigenesis by regulating
anti-inflammatory miRNA. Altogether, these results indicate that
resveratrol could be used to prevent inflammation and reduce
the risk of colon carcinogenesis in IBD.
Resveratrol in human clinical trials
Human clinical trials of the potential therapeutic, or, better,
ameliorating effects of resveratrol in IBD are few (Table 3).
Recently, a randomised, double-blind, placebo-controlled clin-
ical trial evaluating the effects of resveratrol supplementation on
inflammatory biomarkers and the quality of life of patients with
UC was carried out. In this study, a dose of 0·5 g/d of resveratrol
was given to patients for 6 weeks. The authors observed that
the plasma levels of high-sensitivity C-reactive protein in the
resveratrol-treated group were reduced. Furthermore, plasma
TNF-α and NF-κB p65 levels were decreased in response to
resveratrol. The quality of life of these patients was improved,
and the clinical colitis activity index score was significantly
decreased when compared with the placebo group(99). Fur-
thermore, the oxidative status of patients with mild to moderate
UC markedly improved – activity of superoxide dismutase and
total antioxidant capacity were increased, whereas antioxidant
malondialdehyde levels were decreased – in patients who were
given resveratrol(100).
In another study, patients with colorectal cancer were
given daily doses of resveratrol of 0·5 and 1g/d for 8 d before
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surgery. Interestingly, the levels of both resveratrol and its
metabolites that were found in biopsy tissue samples were similar
to the concentrations used in order to reduce tumorigenesis
in vitro(75).
Taken together, these studies suggest that resveratrol can
improve the quality of life of patients with IBD, and decrease
inflammation and oxidative stress.
Conclusions
A number of in vitro and animal studies have shown that resver-
atrol may reduce the severity of intestinal inflammation in models
of IBD. The beneficial effects of resveratrol were attributed to a
variety of mechanisms that ultimately lead to the inhibition of
several key components of the inflammatory cascade. The most
commonly described effects were inhibition of NF-κB activation,
decreased COX-2 expression, reduction of proinflammatory cyto-
kines, decreased PGE2, and PGD2 levels and neutrophil infiltration,
and attenuation of reactive species production. Resveratrol has also
been shown to promote the reduction of bacterial translocation and
to alter the intestinal microbial composition. Resveratrol also
appeared to inhibit tumorigenesis by modulating a variety of signal
transduction pathways and programmed cell death (Fig. 4).
Nevertheless, the limited use of resveratrol metabolites in in vitro
studies, the doses applied in animal models, and, most of all, the
paucity of human intervention studies drastically limit the relevance
of these results, as a real translation into a preventative strategy
towards IBD is far from confirmed. For this reason, if resveratrol has
to be kept within the list of dietary phytochemicals with a relevant
anti-inflammatory effect in the framework of IBD, future research
should focus on three main topics: (i) increasing the efficacy and
bioavailability of resveratrol, (ii) investigating the anti-inflammatory
effects of resveratrol metabolites on chronic inflammatory diseases
such as IBD, while also determining possible antagonistic or
synergistic interactions of these metabolites with resveratrol, and
(iii) performing a number of trials in human subjects providing
resveratrol as a strategic phytochemical to prevent or as a com-
plementary treatment for IBD.
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Table 3. Summary of findings related to resveratrol intake in patients with inflammatory bowel disease
Study design Population
Subjects
(sex, n, age) Intervention Control/comparator Duration Outcomes Reference
Pre- and post-test UC patients F and M: 49,
22–54 years
Resveratrol
capsules,
500mg/d
– 6 weeks ↓ Plasma hs-CRP level, ↓
TNF-α level, ↓ PBMC NF-κB
activation, ↑ IBDQ-9 score,
↔ SCCAI score
Samsami-Kor et al.(99)
Pre- and post-test UC patients F and M: 56,
21–54 years
Resveratrol
capsules,
500mg/d
– 6 weeks ↑ Plasma SOD activity, ↑
plasma TAC, ↓ plasma MDA
level, ↑ IBDQ-9 score, ↔
SCCAI score
Samsamikor et al.(100)
UC, ulcerative colitis; F, female; M, male; ↓, decrease; hs-CRP, high-sensitivity C-reactive protein; PBMC, peripheral blood mononuclear cells; ↑, increase; IBDQ-9, nine-item
inflammatory bowel disease questionnaire; ↔, no change; SCCAI, simple clinical colitis activity index; SOD, superoxide dismutase; TAC, total antioxidant capacity; MDA,
malondialdehyde.
Resveratrol
TLR4 | NF-κB 
SIRT1
Pro-inflammatory cytokines
Signalling molecules
COX-2
MAPK
ICAM and VCAM
Neutrophil infiltration
Antioxidant defences
Oxidative stress
Fig. 4. Pathways regulated by resveratrol in the intestinal mucosa. SIRT1, sirtuin 1; TLR4, Toll-like receptor 4; NF-κB, nuclear factor κ light-chain-enhancer of activated
B cells; COX-2, cyclo-oxygenase 2; ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule; MAPK, mitogen-activated protein kinase.
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